Hiring in life sciences? Share your open positions with our professional community. Read more Close

Your cookie settings

This site uses cookies. Some cookies are essential to make the site work and others help us to improve our services. Read more about cookies in our Privacy policy.

Choose your cookie preferences:

Advertisement

Targeting leukemia stem cells in unfit acute myeloid leukemia with a CD70-directed third agent: promise and caveats from the ELEVATE trial. Comment on: "Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study".

Created on 01 Oct 2026

Authors

Tianxin Lyu, Yanli Zhang

Published in

Haematologica. Oct 01, 2026. Epub Oct 01, 2026.

Abstract

Not available.

PMID:
42817840
Bibliographic data and abstract were imported from PubMed on 01 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Sign in to post a review. Add review
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 17
  • Comments 0

Recommended by

  • No recommendations yet.

Do you recommend this? Please sign in. Yes No

Recommended

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement